Sugi Predict

Sugi Predict / Compounds / SCHEMBL516558

SCHEMBL516558

SCHEMBL516558

NS(=O)(=O)c1cnc2ccccc2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 6/20 0.57
▸ LMNA P02545 4/20 0.57
▸ MAPT P10636 3/20 0.57
▸ ALDH1A1 P00352 3/20 0.57
▸ HPGD P15428 3/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ KMT2A Q03164 1/20 0.54
▸ POLB P06746 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ CA12 O43570 3/20 0.47
▸ CA1 P00915 3/20 0.47
▸ CA2 P00918 3/20 0.47
▸ CA9 Q16790 2/20 0.47
▸ CA4 P22748 2/20 0.47
▸ CA7 P43166 2/20 0.47
▸ CA14 Q9ULX7 2/20 0.47
▸ CA6 P23280 1/20 0.47
▸ CA5A P35218 1/20 0.47
▸ CA13 Q8N1Q1 1/20 0.47
▸ ALOX15 P16050 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27749003 0.87 HTT (0.47) HTTLMNAMAPTALDH1A1HPGD
SCHEMBL1224946 0.84 HTT (0.44) HTTLMNAMAPTALDH1A1HPGD
SCHEMBL3458498 0.80 HTT (0.57) HTTLMNAMAPTALDH1A1HPGD
SCHEMBL30665799 0.80 HTT (0.57) HTTLMNAMAPTALDH1A1HPGD
SCHEMBL3521038 0.80 HTT (0.58) HTTLMNAMAPTALDH1A1HPGD
SCHEMBL11127797 0.79 HTT (0.53) HTTLMNAMAPTALDH1A1HPGD
Hydrochloric Acid SCHEMBL28203639 0.78 HTT (0.56) HTTLMNAMAPTALDH1A1HPGD
SCHEMBL27914649 0.78 HTT (0.56) HTTLMNAMAPTALDH1A1HPGD
SCHEMBL27767382 0.77 HTT (0.76) HTTLMNAMAPTALDH1A1HPGD
SCHEMBL5117540 0.77 HTT (0.54) HTTLMNAMAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101282947-A Acenaphthoquinoxaline sulfonamide derivative, optical crystal film and preparation method thereof CRYSOPTIX LTD (JP) 2008-10-08 — — CN claimed
CN-112839931-B 1,2,3, 4-tetrahydroquinoxaline derivative, and preparation method and application thereof 上海和誉生物医药科技有限公司 2023-12-01 — — CN disclosed
US-11370776-B2 Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors INFLAZOME LIMITED (IE) 2022-06-28 — — US disclosed
US-11370776-B2 Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors INFLAZOME LIMITED (IE) 2022-06-28 — — US disclosed
CN-109142572-B Synchronous extraction and detection analysis method for multiple drugs in environmental multi-media 中南大学 2021-06-04 — — CN disclosed
US-20200270227-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS INFLAZOME LIMITED (IE) 2020-08-27 — — US disclosed
US-20200270227-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS INFLAZOME LIMITED (IE) 2020-08-27 — — US disclosed
EP-3649112-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS Inflazome Limited (IE) 2020-05-13 — — EP disclosed
EP-2118076-B1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO SA (CH) 2019-09-04 — — EP disclosed
CN-105960404-B The inhibitor of bruton's tyrosine kinase 药品循环有限责任公司 2019-09-03 — — CN disclosed
CN-1720226-A Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases CELGENE CORP (US) 2006-01-11 — — CN disclosed
CN-1678585-A therapeutic agent for treating pain EURO CELTIQUE SA (LU) 2005-10-05 — — CN disclosed
US-20050043310-A1 Preparation of quinoxaline compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-24 — — US disclosed
WO-2005016896-A1 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-24 — — WO disclosed
WO-2005016897-A1 PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-24 — — WO disclosed
US-20050038032-A1 Quinoxaline compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-17 — — US disclosed
WO-2005007099-A2 PKB INHIBITORS AS ANTI-TUMOR AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2005-01-27 — — WO disclosed
US-5863917-A ANXIOLYTIC AGENT, ANTICONVULSANTS, ANALGESICS AND NEUROPROTECTIVES. PFIZER, INC. (US) 1999-01-26 — — US disclosed
WO-1997031902-A1 QUINOXALINE DERIVATIVES USEFUL IN THERAPY PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) 1997-09-04 — — WO disclosed
EP-0792874-A1 Quinoxaline derivatives useful in therapy Pfizer Limited (GB) 1997-09-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11370776-B2 Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors NLRP3, NOD1, NLRP1 HTT 1044/4885LMNA 1137/4885MAPT 2890/4885
US-20200270227-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS NLRP3, NOD1, NLRP1 HTT 1044/4885LMNA 1137/4885MAPT 2890/4885
US-20050043310-A1 Preparation of quinoxaline compounds CCKAR, CCKBR, GIPR HTT 2225/4885LMNA 2703/4885MAPT 4849/4885
US-20050038032-A1 Quinoxaline compounds CCKAR, CCKBR, GIPR HTT 1570/4885LMNA 4073/4885MAPT 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.